HMHamid Mirzaei

Hamid Mirzaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hamid Mirzaei has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • David C. Trudgian

    From the ‡Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390

    3 shared publications
  • Mohammad Goodarzi

    Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX, 75390, USA

    3 shared publications
  • Andrew Lemoff

    Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, USA

    2 shared publications
  • Bahar Saremi

    University of Texas at Arlington and University of Texas Southwestern Medical Center Joint Biomedical Engineering Program, Arlington, TX, 75390, USA

    2 shared publications
  • Rueyling Lin

    Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX, USA

    2 shared publications
  • Xiaofeng Guo

    From the ‡Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390

    2 shared publications

Latest Publications

  • Open Access

    Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1/5 activation and lifespan extension in C. elegans

    by Esmaeil Dehghan, Mohammad Goodarzi, Bahar Saremi, Rueyling Lin, Hamid Mirzaei

    Therapeutic activation of mitochondrial function has been suggested as an effective strategy to combat aging. Hydralazine is an FDA-approved drug used in the treatment of hypertension, heart failure and cancer. Hydralazine has been recently shown to promote lifespan inC. elegans, rotifer and yeast through a mechanism which has remained elusive. Here we report cAMP-dependent protein kinase (PKA) as the direct target of hydralazine. Using in vitro and in vivo models, we demonstrate a mechanism in which binding and stabilization of a catalytic subunit of PKA by hydralazine lead to improved mitochondrial function and metabolic homeostasis via the SIRT1/SIRT5 axis, which underlies hydralazine’s prolongevity and stress resistance benefits. Hydralazine also protects mitochondrial metabolism and function resulting in restoration of health and lifespan inC. elegansunder high glucose and other stress conditions. Our data also provide new insights into the mechanism(s) that explain various other known beneficial effects of hydralazine.


  • Open Access

    Inert and seed-competent tau monomers suggest structural origins of aggregation

    by Hilda Mirbaha, Dailu Chen, Olga A Morazova, Kiersten M Ruff, Apurwa M Sharma, Xiaohua Liu, Mohammad Goodarzi, Rohit V Pappu, David W Colby, Hamid Mirzaei, et al.

    Tauopathies feature progressive accumulation of tau amyloids. Pathology may begin when these amplify from a protein template, or seed, whose structure is unknown. We have purified and characterized distinct forms of tau monomer—inert (Mi) and seed-competent (Ms). Recombinant Ms triggered intracellular tau aggregation, induced tau fibrillization in vitro, and self-assembled. Ms from Alzheimer’s disease also seeded aggregation and self-assembled in vitro to form seed-competent multimers. We used crosslinking with mass spectrometry to probe structural differences in Mi vs. Ms. Crosslinks informed models of local peptide structure within the repeat domain which suggest relative inaccessibility of residues that drive aggregation (VQIINK/VQIVYK) in Mi, and exposure in Ms. Limited proteolysis supported this idea. Although tau monomer has been considered to be natively unstructured, our findings belie this assumption and suggest that initiation of pathological aggregation could begin with conversion of tau monomer from an inert to a seed-competent form.


  • Open Access

    Hydralazine induces stress resistance and extends C. elegans lifespan by activating the NRF2/SKN-1 signalling pathway

    by Esmaeil Dehghan, Yiqiang Zhang, Bahar Saremi, Sivaramakrishna Yadavali, Amirmansoor Hakimi, Maryam Dehghani, Mohammad Goodarzi, Xiaoqin Tu, Scott Robertson, Rueyling Lin, et al.

    Nuclear factor (erythroid-derived 2)-like 2 and itsCaenorhabditiselegansortholog, SKN-1, are transcription factors that have a pivotal role in the oxidative stress response, cellular homeostasis, and organismal lifespan. Similar to other defense systems, the NRF2-mediated stress response is compromised in aging and neurodegenerative diseases. Here, we report that the FDA approved drug hydralazine is a bona fide activator of the NRF2/SKN-1 signaling pathway. We demonstrate that hydralazine extends healthy lifespan (~25%) in wild type and tauopathy modelC. elegansat least as effectively as other anti-aging compounds, such as curcumin and metformin. We show that hydralazine-mediated lifespan extension is SKN-1 dependent, with a mechanism most likely mimicking calorie restriction. Using both in vitro and in vivo models, we go on to demonstrate that hydralazine has neuroprotective properties against endogenous and exogenous stressors. Our data suggest that hydralazine may be a viable candidate for the treatment of age-related disorders.


  • Abstract 535: Selected reaction monitoring (SRM)-based assay for the quantification of biomarkers in human breast cancer tissue

    by Alimatou M. Tchafa, Andrew S. Lemoff, Hamid Mirzaei

    Background: Breast cancer is a heterogeneous disease that has remained the second leading cause of cancer-related death in women despite the advances in research over the past decades. Numerous studies have shown that just like in other cancers, early detection drastically improves survival rates. Breast cancer diagnosis is currently dependent on the differential expression of key proteins (biomarkers) that allow for classification, staging and identification of proper therapies. However, because of its heterogeneity, accurate measurement of these biomarkers remains challenging and subjective. Antibody-based techniques such as immunohistochemistry are currently the standard methods of biomarker measurements in breast cancer. With the improvement of genomic and proteomic technology, the number of validated biomarkers is increasing at a faster pace than the number of corresponding clinical assays, preventing the quick translation from the bench to the clinic. Selected reaction monitoring (SRM) is a robust and accurate mass spectrometry-based method that can be used to simultaneously quantify subgroups of protein-specific peptides within any complex protein mixture. The goal of this study is to develop an SRM-based assay for simultaneous detection of 40 biomarkers in tissues. Method: Our panel of biomarkers consists of well-established proteins whose expression correlates with breast cancer aggressiveness and therapy, such as estrogen receptor (ER), HER2 and progesterone receptor (PR). It also includes cellular characterization markers like E-cadherin, fibronectin and vimentin that can aid in better categorization of cancer types. Peptides specific to beta-actin and GAPDH are used as internal controls. We have access to over 2000 characterized breast tissue samples available at the UT Southwestern Medical Center tissue repository. These paraffin-embedded tissues are laser-capture micro-dissected and digested prior to SRM measurements. For validation, we compare the SRM measurements to current bench-top techniques such as immunohistochemistry and Western blot. Results: Using our current method, we have successfully quantified the levels of ER, PR, Her2, and fibronectin on 2.4mm2 breast tissues. Additional experiments are underway to quantify the levels of these and additional proteins in additional samples and to compare their expression to their clinical and pathology reports. Conclusion: Development of high quality antibody assays is time consuming and requires extensive resources and efforts. In addition immunohistochemistry assays cannot be multiplexed. This project will provide a faster, cost-effective, and multiplexable method for breast cancer biomarkers detection and quantification. Future studies will focus on measuring the levels of the same biomarkers in serum samples. Altogether, it will allow for a quick validation platform as new biomarkers are identified. Citation Format: Alimatou M. Tchafa, Andrew S. Lemoff, Hamid Mirzaei. Selected reaction monitoring (SRM)-based assay for the quantification of biomarkers in human breast cancer tissue. []. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl): nr 535. doi:10.1158/1538-7445.AM2015-535

  • Detection of FGF15 in Plasma by Stable Isotope Standards and Capture by Anti-peptide Antibodies and Targeted Mass Spectrometry

    by Takeshi Katafuchi, Daria Esterházy, Andrew Lemoff, Xunshan Ding, Varun Sondhi, Steven A. Kliewer, Hamid Mirzaei, David J. Mangelsdorf


  • Open Access

    Confetti: A Multiprotease Map of the HeLa Proteome for Comprehensive Proteomics

    by Xiaofeng Guo, David C. Trudgian, Andrew Lemoff, Sivaramakrishna Yadavalli, Hamid Mirzaei


  • Open Access

    GOAT – A simple LC‐MS/MS gradient optimization tool

    by David C. Trudgian, Roman Fischer, Xiaofeng Guo, Benedikt M. Kessler, Hamid Mirzaei

    Modern nano‐HPLC systems are capable of extremely precise control of solvent gradients, allowing high‐resolution separation of peptides. Most proteomics laboratories use a simple linear analytical gradient for nano‐LC‐MS/MS experiments, though recent evidence indicates that optimized non‐linear gradients result in increased peptide and protein identifications from cell lysates. In concurrent work, we examined non‐linear gradients for the analysis of samples fractionated at the peptide level, where the distribution of peptide retention times often varies by fraction. We hypothesized that greater coverage of these samples could be achieved using per‐fraction optimized gradients. We demonstrate that the optimized gradients improve the distribution of peptides throughout the analysis. Using previous generation MS instrumentation, a considerable gain in peptide and protein identifications can be realized. With current MS platforms that have faster electronics and achieve shorter duty cycle, the improvement in identifications is smaller. Our gradient optimization method has been implemented in a simple graphical tool (GOAT) that is MS‐vendor independent, does not require peptide ID input, and is freely available for non‐commercial use at http://proteomics.swmed.edu/goat/


  • Cloud CPFP: A Shotgun Proteomics Data Analysis Pipeline Using Cloud and High Performance Computing

    by David C. Trudgian, Hamid Mirzaei

    We have extended the functionality of the Central Proteomics Facilities Pipeline (CPFP) to allow use of remote cloud and high performance computing (HPC) resources for shotgun proteomics data processing. CPFP has been modified to include modular local and remote scheduling for data processing jobs. The pipeline can now be run on a single PC or server, a local cluster, a remote HPC cluster, and/or the Amazon Web Services (AWS) cloud. We provide public images that allow easy deployment of CPFP in its entirety in the AWS cloud. This significantly reduces the effort necessary to use the software, and allows proteomics laboratories to pay for compute time ad hoc, rather than obtaining and maintaining expensive local server clusters. Alternatively the Amazon cloud can be used to increase the throughput of a local installation of CPFP as necessary. We demonstrate that cloud CPFP allows users to process data at higher speed than local installations but with similar cost and lower staff requirements. In addition to the computational improvements, the web interface to CPFP is simplified, and other functionalities are enhanced. The software is under active development at two leading institutions and continues to be released under an open-source license at http://cpfp.sourceforge.net.